279 related articles for article (PubMed ID: 31407168)
1. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.
Saito R; Kobayashi T; Kashima S; Matsumoto K; Ogawa O
Int J Clin Oncol; 2020 May; 25(5):831-841. PubMed ID: 31407168
[TBL] [Abstract][Full Text] [Related]
2. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
3. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
4. Modeling Tumor Immunology and Immunotherapy in Mice.
Buqué A; Galluzzi L
Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
[TBL] [Abstract][Full Text] [Related]
5. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.
Sanmamed MF; Chester C; Melero I; Kohrt H
Ann Oncol; 2016 Jul; 27(7):1190-8. PubMed ID: 26912558
[TBL] [Abstract][Full Text] [Related]
6. Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy.
Wege AK
BioDrugs; 2018 Jun; 32(3):245-266. PubMed ID: 29589229
[TBL] [Abstract][Full Text] [Related]
7. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
8. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
9. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.
Choi Y; Lee S; Kim K; Kim SH; Chung YJ; Lee C
Exp Mol Med; 2018 Aug; 50(8):1-9. PubMed ID: 30089794
[TBL] [Abstract][Full Text] [Related]
10. Techniques for the generation of humanized mouse models for immuno-oncology.
Yu CI; Marches F; Wu TC; Martinek J; Palucka K
Methods Enzymol; 2020; 636():351-368. PubMed ID: 32178826
[TBL] [Abstract][Full Text] [Related]
11. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
Veeranki OL; Tong Z; Mejia A; Verma A; Katkhuda R; Bassett R; Kim TB; Wang J; Lang W; Mino B; Solis L; Kingsley C; Norton W; Tailor R; Wu JY; Krishnan S; Lin SH; Blum M; Hofstetter W; Ajani J; Kopetz S; Maru D
Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31732509
[TBL] [Abstract][Full Text] [Related]
12. Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.
Chen A; Neuwirth I; Herndler-Brandstetter D
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296949
[TBL] [Abstract][Full Text] [Related]
13. The humanized mouse: Emerging translational potential.
Morton JJ; Alzofon N; Jimeno A
Mol Carcinog; 2020 Jul; 59(7):830-838. PubMed ID: 32275343
[TBL] [Abstract][Full Text] [Related]
14. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
[TBL] [Abstract][Full Text] [Related]
15. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Jin KT; Du WL; Lan HR; Liu YY; Mao CS; Du JL; Mou XZ
Cancer Sci; 2021 Jul; 112(7):2592-2606. PubMed ID: 33938090
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors.
Zhong W; Myers JS; Wang F; Wang K; Lucas J; Rosfjord E; Lucas J; Hooper AT; Yang S; Lemon LA; Guffroy M; May C; Bienkowska JR; Rejto PA
BMC Genomics; 2020 Jan; 21(1):2. PubMed ID: 31898484
[TBL] [Abstract][Full Text] [Related]
17. Mouse Models for Cancer Immunotherapy Research.
Olson B; Li Y; Lin Y; Liu ET; Patnaik A
Cancer Discov; 2018 Nov; 8(11):1358-1365. PubMed ID: 30309862
[TBL] [Abstract][Full Text] [Related]
18. Humanized Mouse Models for Immuno-oncology Drug Discovery.
Kumari R; Feuer G; Bourré L
Curr Protoc; 2023 Aug; 3(8):e852. PubMed ID: 37552031
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.
Pyo DH; Hong HK; Lee WY; Cho YB
Cancer Biol Ther; 2020 Jun; 21(6):495-502. PubMed ID: 32208894
[TBL] [Abstract][Full Text] [Related]
20. Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research.
Overgaard NH; Fan TM; Schachtschneider KM; Principe DR; Schook LB; Jungersen G
ILAR J; 2018 Dec; 59(3):247-262. PubMed ID: 30476148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
